The Shouty Track

Rapid Growth and Rebrand Launch Payference's Position in Fintech Space

Retrieved on: 
Wednesday, June 29, 2022

SUNNYVALE, Calif., June 29, 2022 /PRNewswire-PRWeb/ -- Payference, an all-in-one cash management platform, reports impressive growth, along with a rebrand. In the past three months, the company has doubled the number of registered new users, the volume of collection activities, and payments.

Key Points: 
  • SUNNYVALE, Calif., June 29, 2022 /PRNewswire-PRWeb/ -- Payference , an all-in-one cash management platform, reports impressive growth, along with a rebrand.
  • In the past three months, the company has doubled the number of registered new users, the volume of collection activities, and payments.
  • We offer them uncomplicated cash control with all the functionality they want and none of the extras they don't," says Kumar.
  • Instead of data assembly taking days to complete, finance teams use Payference to capture cash inflow and outflow in real-time.

Oak Hill Bio Announces Formation of Board of Directors

Retrieved on: 
Tuesday, April 12, 2022

The entire Oak Hill team looks forward to working closely with the Board as we advance our pipeline of potentially transformative new medicines.

Key Points: 
  • The entire Oak Hill team looks forward to working closely with the Board as we advance our pipeline of potentially transformative new medicines.
  • Oak Hill Bio was established with the acquisition and license of two clinical-stage and four preclinical investigational therapeutics from Takeda Pharmaceutical Company Limited (Takeda).
  • The members of the Oak Hill Bio Board of Directors are as follows:
    Edwin Moses, Ph.D. has more than 25 years of experience as a chief executive and chair of numerous life science companies.
  • For more information on Oak Hill Bio, visit the companys website at www.oakhillbio.com .

ShouTi Appoints Sharon Tetlow to Board of Directors

Retrieved on: 
Tuesday, March 29, 2022

ShouTi Inc ., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the companys board of directors.

Key Points: 
  • ShouTi Inc ., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the companys board of directors.
  • On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board, said Daniel Welch, Chairman of the Board, ShouTi.
  • Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee.
  • Ms. Tetlow has more than 30 years of financial leadership experience within the life sciences industry.

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Retrieved on: 
Thursday, February 17, 2022

ShouTi Inc. , a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTis pipeline and pursuing drug discovery partnerships.

Key Points: 
  • ShouTi Inc. , a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTis pipeline and pursuing drug discovery partnerships.
  • Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery.
  • Its mission is to prosecute the most challenging structure-based drug discovery targets, including G-protein coupled receptors (GPCRs), and deliver discovery assets to ShouTis development pipeline.
  • In addition, Basecamp Bio will explore selective partnerships to tackle high value targets pursued by the biopharmaceutical industry.

ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman

Retrieved on: 
Thursday, January 20, 2022

ShouTi Inc ., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the companys board of directors.

Key Points: 
  • ShouTi Inc ., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the companys board of directors.
  • "It is a true privilege to welcome Dan to ShouTi as Chairman of our board, said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi.
  • He was Chairman, President and CEO of InterMune until its $8.3 billion acquisition by Roche in 2014.
  • Mr. Welch presently serves as Chairman of Ultragenyx Pharmaceutical (NASDAQ: RARE), Chairman of Nuvation Bio (NYSE: NUVB), Executive Chairman of Levo Therapeutics, Executive Chairman of InCarda Therapeutics, and Director of Seagen (NASDAQ: SGEN).

ShouTi Appoints Ding Ding, Ph.D., as Chief Financial Officer

Retrieved on: 
Tuesday, December 21, 2021

ShouTi Inc ., a clinical-stage biopharmaceutical company creating world-class small molecule medicines using advanced computational and structure-based technology, today announced the appointment of Ding Ding, Ph.D., as Chief Financial Officer (CFO).

Key Points: 
  • ShouTi Inc ., a clinical-stage biopharmaceutical company creating world-class small molecule medicines using advanced computational and structure-based technology, today announced the appointment of Ding Ding, Ph.D., as Chief Financial Officer (CFO).
  • She joins ShouTi from Credit Suisse, where she served as the head of APAC Healthcare Investment Banking and Capital Markets.
  • Dr. Ding is an accomplished financial executive with an exceptional track record in the global healthcare investment banking industry, said Dr. Raymond Stevens, Ph.D., Chief Executive Officer.
  • Dr. Ding brings 20 years of experience in healthcare investment banking and equity research in New York, Hong Kong and Shanghai.

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

Retrieved on: 
Wednesday, October 20, 2021

ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).

Key Points: 
  • ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).
  • Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
  • With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations.
  • Joining Dr. Stevens are:
    SVB Leerink acted as exclusive financial advisor for ShouTis Series B financing.